INGN News and Press, Inogen Inc From 11/03/22

Inogen, Inc. (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that management will present at the following investor conferences: Stifel 2022 Healthcare Conference on Tuesday, November 1...

Inogen, Inc. (INGN) Q3 2022 Results Conference Call November 02, 2022 08:00 AM ET Company Participants Agnes Lee - SVP of IR and Strategic Planning Nabil Shabshab - President and CEO Kristin Caltrider - CFO Conference Call Participants Mathew Blackman...

The following slide deck was published by Inogen, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Inogen, Inc. 2022 Q3 - Results - Earnings Call Presentation

Inogen press release ( NASDAQ: INGN ): Q3 Non-GAAP EPS of -$0.18 beats by $0.20 . Revenue of $105.39M (+13.2% Y/Y) beats by $7.67M . On a constant currency basis, total revenue for the period ended September 30, 2022, increased 14.5%. Cash and cash equivale...

Double Digit Year-over-Year Revenue Growth of 13.2% Constant Currency Year-over-Year Revenue Growth of 14.5% Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced fi...

Inogen ( NASDAQ: INGN ) is scheduled to announce Q3 earnings results on Wednesday, November 2nd, before market open. The consensus EPS Estimate is -$0.38 and the consensus Revenue Estimate is $97.72M (+5.0% Y/Y). Over the last 1 year, INGN has beaten EPS estimates ...

Inogen, Inc . (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will issue third quarter 2022 financial results before the market opens on Wednesday, November 2, 2022. On the same day, the Co...

Summary Inogen has been a long-term growth story which has seen real execution challenges in recent years. Current supply chain woes make up for a tough margin picture, yet operational issues have been seen for a couple of years now. Valuations are not too demanding, not in th...

Summary Inogen came in with a mixed set of numbers, however, longer-term structural headwinds remain in situ. The hold rating on INGN remains intact following Q2 earnings, and I've noticed similar themed risks looking ahead. Chief to the downside risk is a further slowdown in ...

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the second quarter, the Baron Discovery Fund was down 22.66% (Institutional Shares), which was 3.41% below the Russell...